The tissue renin-angiotensin system and intracellular signalling

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 1, 2006, Pages 8-13

  Fleming, Ingrid ^a   Kohlstedt, Karin ^a   Busse, Rudi ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Angiotensin converting enzyme; Bradykinin; Type 2 diabetes

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLIZING ENZYME; RENIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE;

ADIPOSE TISSUE; GENE TARGETING; HEART FUNCTION; HUMAN; INSULIN SENSITIVITY; KIDNEY FUNCTION; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; TISSUE LEVEL; VASCULAR DISEASE; DIABETES MELLITUS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; DIABETES MELLITUS; HUMANS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 33645736137     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000196146.65330.ea     Document Type: Review

References (61)

1. Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. Am Heart J 2000; 139 (Suppl. 1):S15-S22.
2. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:564-572.
3. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1:401-406.
4. Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001; 37:1056-1061.
5. Borland JA, Kelsall C, Yacoub MH, et al. Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries. Vascul Pharmacol 2005; 42:99-108.
6. Hooper NM, Keen J, Pappin DJ, et al. Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane. Biochem J 1987; 247:85-93.
7. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214:374-376.
8. Kondoh G, Tojo H, Nakatani Y, et al. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat Med 2005; 11:160-166. This study reports that ACE possesses a glycosylphosphatidylinositol-anchored protein-releasing activity (glycosylphosphatidylinositol hydrolase activity). ACE shed various glycosylphosphatidylinositol-anchored proteins from the cell surface, including TESP5 and PH-20 from sperm membranes; a process that seems to be essential for fertility.
9. Wu Q, Kuo HC, Deng GG. Serine proteases and cardiac function. Biochim Biophys Acta 2005; 1751:82-94. A very informative current review that summarizes the multifunctional actions of different serine proteases.
10. Takai S, Jin D, Muramatsu M, et al. Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci 2004; 25:518-522. A comment highlighting the importance of chymase and chymase inhibition in cases of abdominal aortic aneurysm and angiogenesis.
11. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
12. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-33243.
13. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277:14838-14843.
14. Campbell DJ, Zeitz CJ, Esler MD, et al. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004; 22:1971-1976.
15. Danilczyk U, Eriksson U, Crackower MA, et al. A story of two ACEs. J Mol Med 2003; 81:227-234.
16. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2. Exp Physiol 2005; 90:783-790. A study supporting the concept that ACE2 counteracts the effects of classic RAS activation. ACE2 overexpression protected against angiotensin II-induced cardiac hypertrophy and fibrosis in Sprague-Dawley rats.
17. Donoghue M, Wakimoto H, Maguire CT, et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 2003; 35:1043-1053.
18. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828.
19. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
20. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875-879. A study providing a molecular explanation as to why severe acute respiratory syndrome-coronavirus infection causes severe/lethal lung failure, and suggests treatment with recombinant ACE2 protein or other RAS modulators, i.e. AT1 receptor blocker.
21. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112-116.
22. Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94:978-984.
23. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165:1019-1032.
24. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94:2756-2767.
25. Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15:1295-1302.
26. Tahmasebi M, Puddefoot JR, Inwang ER, et al. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999; 161:317-322.
27. Leung PS, Chan WP, Wong TP, et al. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999; 160:13-19.
28. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35:1270-1277.
29. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-362.
30. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22:1977-1982. A study showing a link between RAS blockade, adiponectin concentration and insulin resistance in patients with essential hypertension.
31. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42:76-81.
32. 2 receptor and supports its involvement in increasing the adipose cell mass and glucose intolerance.
33. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
34. Eggena P, Zhu JH, Clegg K, et al. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 1993; 22:496-501.
35. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89:1138-1146.
36. Filipeanu CM, Henning RH, Nelemans SA, et al. Intracellular angiotensin II: from myth to reality? J Renin Angiotensin Aldosterone Syst 2001; 2:219-226.
37. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
38. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
39. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005; 90:291-298.
40. 2 kinin receptor gene knockout mice. Circ Res 2001; 88:1072-1079.
41. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935.
42. 2 receptors. Circ Res 2004; 94:1623-1629. An impressive study highlighting the complex interactions between RAS and the kallikrein-kinin system.
43. 1 receptors, ACE2 and angiotensin(1-7), and suggesting a role in vascular hypertrophy.
44. Wiemer G, Schölkens BA, Becker RHA, et al. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18:558-563.
45. Benzing T, Fleming I, Blaukat A, et al. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99:2034-2040.
46. Kohlstedt K, Shoghi F, Müller-Esterl W, et al. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res 2002; 91:749-756.
47. Kohlstedt K, Brandes RP, Muller-Esterl W, et al. Angiotensin-converting enzyme is involved in outside-in signalling in endothelial cells. Circ Res 2004; 94:60-67. See Ref. [48•].
48. Kohlstedt K, Busse R, Fleming I. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 2005; 45:126-132. Studies describing an ACE-dependent signalling pathway in endothelial cells that is activated by the binding of an ACE inhibitor to the enzyme.
49. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919-925.
50. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885.
51. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
52. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
53. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473. An informative review summarizing the antidiabetic actions of RAS inhibitors.
54. da Cunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178:9-17.
55. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43:993-1002. An interesting study that reports that some AT1 receptor antagonists act as partial agonists and exert effects on intracellular signalling/gene expression (PPARγ activation).
56. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109:2054-2057. A study (published at roughly the same time as Ref. [55•]} highlighting the ability of specific AT1 receptor antagonists to activate PPARγ activity in adipocytes.
57. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetologica 2005; 42 (Suppl. 1):s9-s16.
58. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110:1507-1512. A well-written up-to-date review discussing the possibilities of RAS inhibition in metabolic syndrome.
59. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11:RA155-RA162. A review focusing on the induction of cytokines, nuclear factor kappa B and oxidative stress by angiotensin II, and discussing the anti-inflammatory actions of RAS inhibition.
60. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 2001; 98:13330-13334.
61. Heimann AS, Favarato MH, Gozzo FC, et al. ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weight. Physiol Genomics 2005; 20:173-182. In-vivo evidence that ACE is involved in the regulation of body weight and fat accumulation, obtained from mice with one or more copies of ACE gene.